

Disclosures

Personal Commercial (38)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
AiRNA	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Allelica	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Allelica	Research/Research Grants	Significant (>= \$5,000)	Prevention
Amgen Inc.	Research/Research Grants	Significant (>= \$5,000)	Prevention
Apple	Research/Research Grants	Significant (>= \$5,000)	Prevention
Apple	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
AstraZeneca Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	Prevention
Bain Capital	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Blackstone Life Sciences	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Bolt	Stock	Modest (< \$5,000)	Other
Boston Scientific	Research/Research Grants ‡ NCT03416920	Significant (>= \$5,000)	Prevention
Bristol-Myers Squibb Company	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Candela	Stock	Modest (< \$5,000)	Other
CRISPR Therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Esperion Therapeutics	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Fosite Capital	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Fosite Labs	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Genentech, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
GV (formerly Google Ventures)	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
HeartFlow	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Magnet Biomedicine	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Merck & Co., Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Mercury	Stock	Modest (< \$5,000)	Other
MyOme	Stock	Modest (< \$5,000)	Other
Novartis Corporation	Research/Research Grants	Significant (>= \$5,000)	Prevention
Novartis Corporation	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Parameter Health	Stock	Modest (< \$5,000)	Prevention
Preciseli	Stock	Modest (< \$5,000)	General Cardiology
Silence Therapeutics	Research/Research Grants	Significant (>= \$5,000)	Prevention
TenSixteen Bio	Stock	Significant (>= \$5,000)	General Cardiology

Company Name	Relationship Category	Compensation Level	Topic Area(s)
TenSixteen Bio	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Tourmaline Bio	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
<i>Spouse/Domestic Partner/Immediate Household Member</i>			
Vertex Pharmaceuticals	Stock	Significant (>= \$5,000)	Other
Vertex Pharmaceuticals	Salary	Significant (>= \$5,000)	Other

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (4)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
American Heart Association	Other - Volunteer Chair, Data Science and Precision Medicine Committee	None (\$0)	Prevention
Fondation Leducq † Fondation Leducq	Research/Research Grants	Significant (>= \$5,000)	Prevention
Manton Foundation	Research/Research Grants	Significant (>= \$5,000)	General Cardiology Prevention
National Institutes of Health	Research/Research Grants	Significant (>= \$5,000)	Prevention

Clinical Trial Enroller (2)

Trial Name	Trial Sponsor	Trial Funding Source
EVOLVE-MI	Amgen	
TRANSFORM	Cleerly	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/1/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.